Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced final data from a randomized, controlled Phase 2 trial of picoplatin in metastatic colorectal cancer (CRC) patients. The study met its primary objective, as picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI regimen) was associated with a statistically significant reduction in [...]

Pfizer Inc. announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas. Sunitinib more than doubled the time patients with pancreatic neuroendocrine tumors lived without disease progression compared with patients treated with [...]

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company’s PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients.

Genomic Health, Inc. (Nasdaq: GHDX) announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer. These data were presented at the 32nd Annual CTRC-AACR San Antonio Breast Cancer [...]

Merck KGaA announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The INSPIRE(a) study will investigate if Stimuvax can extend overall survival in Asian patients with unresectable stage III NSCLC.